Efficacy and Safety of Cilostazol for the Indication of CSPS

This study is currently recruiting participants.

Verified by Korea Otsuka Pharmaceutical Co.,Ltd., October 2006

Sponsored by:	Korea Otsuka Pharmaceutical Co.,Ltd.
Information provided by:	Korea Otsuka Pharmaceutical Co.,Ltd.
ClinicalTrials.gov Identifier:	NCT00216749

Purpose

This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.

Condition	Intervention	Phase
Cerebral Infarction	Drug: Cilostazol	Phase IV

Drug Information available for: Cilostazol

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Case Control, Prospective Study
Official Title:	Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS

Further study details as provided by Korea Otsuka Pharmaceutical Co.,Ltd.:

Estimated Enrollment:	600
Study Start Date:	December 2003
Estimated Study Completion Date:	October 2007

Detailed Description:

This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction.

Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

a) Patient with an experience of cerebral infarction and having a purpose for prevention of recurrence of cerebral infarction.

b) Age: more than 18 years of age

Exclusion Criteria:

a) Unqualified patients judged by study investigator(s)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00216749

Contacts

Contact: Bo Yeon Seo

82-2-3465-5485

byseo@otsuka.co.kr

Locations

Korea, Republic of
Asan Medical Center	Recruiting
Seoul, Korea, Republic of
Contact: S U Kwon, Professor 82-3465-3500

Sponsors and Collaborators

Korea Otsuka Pharmaceutical Co.,Ltd.

Investigators

Study Director:

Bo Youn Seo

Korea Otsuka Pharmaceutical Co.,Ltd.

More Information

Study ID Numbers:	Korea Pletaal CSPS PMS
Study First Received:	September 14, 2005
Last Updated:	October 12, 2006
ClinicalTrials.gov Identifier:	NCT00216749
Health Authority:	Korea: Food and Drug Administration

Keywords provided by Korea Otsuka Pharmaceutical Co.,Ltd.:

Cerebral Infarction Prevention
Cilostazol

Study placed in the following topic categories:

Cilostazol
Necrosis
Cerebral Infarction
Stroke
Vascular Diseases
Central Nervous System Diseases

Brain Ischemia
Ischemia
Brain Infarction
Brain Diseases
Infarction
Cerebrovascular Disorders

Additional relevant MeSH terms:

Respiratory System Agents
Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Hematologic Agents
Nervous System Diseases
Physiological Effects of Drugs
Anti-Asthmatic Agents
Enzyme Inhibitors
Fibrinolytic Agents
Cardiovascular Agents
Protective Agents
Neuroprotective Agents

Pharmacologic Actions
Fibrin Modulating Agents
Phosphodiesterase Inhibitors
Pathologic Processes
Autonomic Agents
Therapeutic Uses
Platelet Aggregation Inhibitors
Cardiovascular Diseases
Peripheral Nervous System Agents
Central Nervous System Agents
Bronchodilator Agents

ClinicalTrials.gov processed this record on January 14, 2009